Comparison of dexmedetomidine and buprenorphine as an adjuvant to bupivacaine during spinal anaesthesia for tibial interlocking nailing surgeries

Authors

  • Amitha S. Department of Anesthesiology, SSMC Tumkur, Karnataka, India
  • Pradeep R. Department of Anesthesiology, ESIC Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20175184

Keywords:

α2-adrenoreceptor agonist, Bupivacaine, Buprenorphine

Abstract

Background: Buprenorphine is being used as an adjuvant to local anaesthetic for spinal anaesthesia since long. Dexmedetomidine is a new drug which has got alpha 2 agonistic property, and is being tried for spinal anesthesia along with bupivacaine in recent times. Settings and Design: This study was conducted in a prospective, randomized, controlled and double-blind manner. The study included ninety American Society of Anaesthesiologists class I and II patients undergoing tibial interlocking nailing surgeries under spinal anaesthesia.

Methods: The patients were randomly divided into three groups (n=30 each) by closed envelope technique. Patients in group 1 received 15 mg of 0.5% hyperbaric bupivacaine, group 2 received 15 mg of 0.5% hyperbaric bupivacaine with 30μg of buprenorphine, and group 3 received 15 mg of 0.5% hyperbaric bupivacaine with 5μg dexmedetomidine for spinal anesthesia. The duration of motor and sensory blockade and any adverse events were recorded. Data were analysed using Chi-square test or Fisher’s exact test for categorical data and analysis of variance for continuous data. A value of P<0.05 was considered as statistically significant.

Results: In our study the subjects in group 3 (dexmedetomidine) group had significantly longer period of motor blockade (240±20min) and sensory blockade (180±22.2min) compared to other groups, which is statistically significant (P=0.0001 and P= 0.006 respectively). The time to first request of analgesic in the post-operative period was also longer (240±30.2min) in dexmedetomidine group when compared with other groups (P=0.0001). There were no untoward complications (hypotension, sedation) in any groups.

Conclusions: We concluded that dexmedetomidine (5μg) with bupivacaine for spinal anesthesia gives significantly longer duration of sensory and motor blockade, than buprenorphine (30μg) with bupivacaine for spinal anaesthesia.

References

Mahendru V, Tewari A, Katyal S, Grewal A, Singh MR, Katyal R. A comparison of intrath-ecal dexmedetomidine, clonidine, and fentanyl as adjuvants to hyperbaric bupivacaine for lower limb surgery: A double blind controlled study. J Anaesthesiol Clin Pharmacol. 2013;29(4):496-502.

Gupta M, Shailaja S, Hegde KS. Comparison of intrathecal dexmedetomidine with bu-prenorphine as adjuvant to bupivacaine in spinal anaesthesia. J Clin Diagn Res. 2014;8(2):114-7.

Abdelhamid SA, El-lakany MH (2013) Intrathecal dexmedetomidine: Useful or not? J Anesth Clin Res. 2013;4:351.

Gupta R, Verma R, Bogra J, Kohli M, Raman R, Kushwaha JK. A Comparative study of intrathecal dexmedetomidine and fentanyl as adjuvants to Bupivacaine. J Anaesthesiol Clin Pharmacol. 2011; 27(3):33943.

Eidhea, Shafie MA, Youssef H. Dose-related prolongation of hyperbaric bupivacaine Spinal anesthesia by dexmedetomidine. Ain Shams J Anesthesiol. 2011;4:83-95.

Kanazi GE, Aouad MT, Jabbour-Khoury SI, Jazzar AL, Alameddine MM, Al-Yaman R, et al. Effect of low-dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal block. Acta Anaesthesiol Scand. 2006;50(2):222-7.

Kalso E, Poyhia R, Rosenberg P. Spinal anti-nociception by dexmedetomidine, a highly selective a2-adrenergic agonist. Pharmacol Toxicol. 1991; 68(2):140-3.

Asano T, Dohi S, Ohta S, Shimonaka H, Lida H. Anti-nociception by epidural and systemic alpha 2 adrenoreceptor agonists and their binding affinity in rat spinal cord and brain. Anesth Analg. 2000; 90(2):400-7.

Shah A, Patel I, Gandhi R. Haemodynamic effects of intrathecal dexmedetomidine added to ropivacaine intraoperatively and for postoperative analgesia. Int J Basic Clin. 2013;2:26-9.

Eisenach JC, De Kock M, Klimscha W. Alpha (2)-adrenergic agonists for regional anes-thesia. A clinical review of clonidine (1984-1995). Anesthesiol.1996;85(3):655-74.

Bromage PR. A comparison of the hydrochloride and carbon dioxide salts of lidocaine and prilocaine in epidural analgesia. Acta Anaesthesiologica Scandinavica. 1965;9:55-69.

Graham AC, McClue JH. Quantitative assessment of motor block in laboring women re-ceiving epidural analgesia. Anaesthes. 2001;56:470-6.

Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxolone-alphadalone. Br Med J. 1974;2(5920):656-9.

Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Research in Nursing and Health. 1990; 13:227-36.

Kim JE, Kim NY, Lee HS, Kil HK. Effects of intrathecal dexmedetomidine on low-dose bu-pivacaine spinal anesthesia in elderly patients undergoing transurethral prostatectomy. Biol Pharm Bull. 2013;36(6):959-65.

Singh R, Shukla. A randomized, controlled study to compare the effect of intrathecal clonidine and dexmedetomidine on sensory analgesia and motor block of hyperbaric bupivacaine. JLS. 2012;2(4): 24-33.

Niu XY, Ding XB, Guo T, Chen MH, Fu SK, Li Q. Effects of intravenous and Intrathecal dex-medetomidine in spinal anesthesia: a meta-analysis. CNS Neurosci Ther. 2013;19(11):897-904.

Bulow NM, Barbosa NV, Rocha JB. Opioid consumption in total intravenous anesthesia is reduced with dexmedetomidine: a comparative study with remifentanil in gynecologic video laparoscopic surgery. J Clin Anesth. 2007;19(4): 280-5.

Ding Z, Raffa RB. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol. 2009; 157:831-43.

Leffler A, Frank G, Kishner K, Niedermirtl F, Koppert W, Reeh PW, et al. Local anesthet-ic-like inhibition of voltage-gated Na(+) channels by the partial μ-opioid receptor agonist buprenorphine. Anesthesiol. 2012;116:1335-46.

Downloads

Published

2017-11-22

Issue

Section

Original Research Articles